FILE:CELG/CELG-8K-20071220160500.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
o
o
o
 
 
 
ITEM 8.01 OTHER EVENTS
On December 20, 2007, Celgene Corporation announced that Chief Executive Officer Sol J. Barer, Ph.D., will present fourth quarter and full-year 2007 and 2008 guidance during a presentation at the JP Morgan Healthcare Conference on Monday, January 7, 2008 at 11:30 am EST.
Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1  Press Release dated December 20, 2007
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Exhibit 99.1
Contact:
 Celgene Corporation (NASDAQ: CELG) today announced Chief Executive Officer Sol J. Barer, Ph.D., will present fourth quarter and full-year 2007 and 2008 guidance during a presentation at the JP Morgan Healthcare Conference on Monday, January 7, 2008 at 11:30 am EST. The event will be webcast live and will be available in the investor relations section of the Companys Web site at www.celgene.com.
SUMMIT, NJ  (December 20, 2007)
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Companys website at www.celgene.com.
This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under the Companys control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and other factors described in the Companys filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports.


